REGENXBIO Inc. (RGNX) Cash Flow Statement

Nine of the last ten quarters show negative operating cash flow, meaning reported profitability remains disconnected from actual cash generation; the 2026Q2 gap appears driven largely by a $103.3M working capital outflow rather than operating deterioration per se, which warrants investigation into whether the earnings are recurring or settlement-related. Even excluding that swing, prior quarters show net losses narrowing toward positive net income without any corresponding move in operating cash flow, suggesting the earnings inflection flagged in the income statement analysis has not translated into self-funded operations.

Quarterly free cash flow has ranged from positive $32.6M in 2025Q1 to negative $77.4M in 2026Q1, with no discernible improving trend; the 2026Q2 shortfall of $63.0M is wider than the $49.7M recorded in 2025Q2, implying that milestone revenue timing has not structurally reduced the funding requirement. Because FCF margins have swung between positive 36.6% and negative 189.9% within the period, investors should treat any extrapolation of the most recent quarter's revenue as unreliable for underwriting the cash trajectory.

Working capital has been volatile throughout the ten-quarter window, ranging from positive $16.4M to negative $103.3M, indicating that cash conversion is being driven by milestone recognition and settlement timing rather than a stable operating cycle — no predictable pattern of collections versus payables emerges to guide near-term cash forecasting. The size of the 2026Q2 outflow relative to the quarter's $108M revenue suggests material cash obligations may be attached to revenue events not fully visible in the income statement, and investors should monitor subsequent quarters to determine whether this represents a recurring timing pattern or a one-time settlement.

The absence of shareholder returns despite two quarters of positive net income suggests the cash position is being conserved to fund ongoing research and development rather than distributed, which is consistent with a pre-commercial-stage capital allocation profile. With capex averaging well under $1M per quarter against cumulative burn of this magnitude, the company appears reliant on external financing rather than internally generated cash; the durability of that access, and any dilutive terms attached to it, warrants further scrutiny beyond what the cash flow statement alone reveals.